Hatice Odabas

Lung cancer in women: a single institution experience with 50 patients.

BACKGROUND Lung cancer is the most common cause of cancer-related death worldwide. The incidence of lung cancer is aproximately 7-8 thousand percent in Turkish women. In this study, we aimed to evaluate the clinical, pathological properties and survival data of female patients with lung cancer who were treated in our center. MATERIALS AND METHODS From 2007 to 2012, 50 women with lung cancer were enrolled. Patient data were evaluated retrospectively. RESULTS The median age was 61 (40-81). Forty patients (80%) were diagnosed with non small cell lung cancer (NSCLC), 10 patients (20%) were small cell carcinoma (SCC). Twelve (24%) patients were smokers and 13 of 16 non-smokers had a history of exposure to asbestos. The most common histologic subtype was adenocarcinoma (46%) and this accounted for 71% in patients with exposure to asbestos. The most common initial Eastern Cooperative Oncology Group (ECOG) performance score was 1 (24 patients, 48%) and initial stage was IV (25 patients, 50%) in the study group. During the median 15 months (1-96 months) followup period: 1 year overall survival (OS) was 68%, 2year overall survival was 36% and the median survival time was 19 months. According to univariate analysis, poor ECOG performance status, advanced stage, anemia and weight loss at time of diagnosis were negative prognostic factors. However, adenocarcinoma sub-type was a positive prognostic factor. CONCLUSIONS In this study NSCLC sub-type, poor ECOG performance score, advanced stage, anemia and weight loss were prognostic factors in Turkish women with lung cancer.

Pretreatment PET/CT Standardized Uptake Values Play a Role in Predicting Response to Treatment and Survival in Patients with Small Cell Lung Cancer

Background: We investigated the role of standardized uptake values (SUVs) of the primary tumor in small cell lung cancer (SCLC) patients. Patients and Methods: The relationship between SUV and response to treatment was investigated using receiver operating characteristic (ROC) curve analysis, and the efficient cut-off value for detecting response to treatment was determined. The effects of SUV on response to treatment and survival were investigated. Results: 90 patients with a median age of 58 years (range 39-83 years) were included. Median follow-up was 11 months. The suitable cut-off SUV for determination of response was found to be 10 in ROC analysis. The sensitivity and specificity of this value were 85.7% (95% confidence interval (95% CI) 63-96) and 61.8% (95% CI 49-73) (area under the curve 0.783; p = 0.0001), respectively. The overall objective response rate in patients with involvement above the cut-off value was 93.3% compared to 59.1% in those with involvement below the cut-off value (p < 0.0001). In uni- and multivariate analysis, favorable effects of limited-stage disease on response to treatment were established (p < 0.05). The effect of an SUV higher than the cut-off value on progression-free survival was borderline (p = 0.085). Conclusion: These data may contribute to identifying prognostic disease characteristics and response to treatment.

Prognostic factors of patients who received chemotherapy after cranial irradiation for non-small cell lung cancer with brain metastases: A retrospective analysis of multicenter study (Anatolian Society of Medical Oncology)

Purpose: Almost half of all patients diagnosed with non-small cell lung cancer (NSCLC) have distant metastases at presentation. One-third of patients with NSCLC will have brain metastases. Without effective treatment, the median survival is only 1 month. However, it is difficult to treat brain metastases with systemic chemotherapy since the agents have difficulty crossing the blood-brain barrier. Therefore, it is important to estimate the patients survival prognosis. The aim of this study was to analyze prognostic factors for survival in Turkish patients who received chemotherapy after cranial irradiation for NSCLC with brain metastases. Methods: We retrospectively reviewed 698 patients with brain metastases resulting from NSCLC. Ten potential prognostic variables were chosen for analysis. Univariate and multivariate analyses were conducted to identify prognostic factors associated with overall survival (OS). Results: Among the 10 variables for univariate analysis, six were identified to have prognostic significance; these included sex, smoking history, histology, number of brain metastases, extracranial metastases, and neurosurgical resection. Multivariate analysis by the Cox proportional hazard model showed that a smoking history, extracranial metastases, and neurosurgical resection were independent negative prognostic factors for OS. Conclusion: Smoking history, extracranial metastases, and neurosurgical resection were considered independent negative prognostic factors for OS. These findings may facilitate pretreatment prediction of survival and can be used for selecting patients for more appropriate treatment options.

Hormone receptor status and survival of medullary breast cancer patients. A Turkish cohort

Objectives: To analyze the relationship between clinical features, hormonal receptor status, and survival in patients who were diagnosed with medullary breast cancer (MBC). Methods: Demographic characteristics, histopathological features, and survival statuses of 201 patients diagnosed with MBC between 1995 and 2015 were retrospectively recorded. Survival analyses were conducted with uni- and multivariate cox regression analysis. Results: Median follow-up time was 54 (4-272) months. Median patient age at the time of diagnosis was 47 years old (26-90). Of the patients, 91.5% were triple negative. Five-year recurrence free survival time (RFS) rate was 87.4% and overalll survival (OS) rate 95.7%. For RFS, progesterone receptor (PR) negativity, atypical histopathological evaluation, absence of lymphovascular invasion, smaller tumor, lower nodal involvement were found to be favourable prognostic factors by univariate analysis (p<0.05). The PR negativity and smaller tumor were found to be favourable factors by univariate analysis (p<0.05). However, none of these factors were determined as significant independent prognostic factors for OS (p>0.05). Conclusion: Turkish MBC patients exhibited good prognosis, which was comparable with survival outcomes achieved in the literature. The PR negativity was related to a better RFS and OS rates.

1204PTHREE DIFFERENT CHEMOTHERAPY COMBINATIONS WITH CONCURRENT THORACIC RADIATION FOR PATIENTS WITH STAGE III NON-SMALL CELL LUNG CANCER

ABSTRACT Aim: Stage III non-small cell lung cancer (NSCLC) is one of the most controversial areas in managing lung cancer and gives a chance to clinicians to practice the art of medicine. The aim of the current study was to compare three chemotherapy regimens commonly used concurrently with radiotherapy in terms of efficacy and safety. Methods: Histologically or cytologically proven patients with NSCLC were included in this study. Clinical data including gender, age, performance status, histological subtype, chemotherapy regimen were recorded. During the concurrent chemoradiation phase, patients were administered the following: cisplatin-etoposide (PE) arm: cisplatin (50mg/m2) on days 1, 8, 29, 36, and etoposide (50mg/m2) on days 1 to 5 and 29 to 33; cisplatin-docetaxel (PD) arm: docetaxel (20mg/m2) and cisplatin (20 mg/m2) on day 1 every week; carboplatin-paclitaxel (PC) arm: carboplatin (AUC2) and paclitaxel (45 mg/m2) on day 1 every week. The primary tumor and involved nodes received 60 Gy in 2-Gy fractions over 5 to7 weeks. Results: Between January 2003 and February 2014, a total of 227 patients were evaluated in the study. Median follow-up time was 13 months (2-101). There were 27 females (11.9%) and 200 males (88.1%) patients with a median age of 61 (38-82) years. 57 patients (25.1%) were not able to receive the whole preplanned dose of chemotherapy, due either to dose reduction (n = 33) or chemotherapy cessation (n = 24). Dose reductions were applied to 11 patients (12.6%) in the PC group, 6 patients (12 %) in the PE group and 16 patients (17.8%) in the PD group as a result of toxicities ( p = :0.530). The PD group had higher rates of esophagitis, mucositis and anemia (p Conclusions: Concurrent chest radiotherapy with PC, PD or PE is well-tolerated and effective in patients with locally advanced NSCLC. These therapeutic approaches have different toxicity profiles and survival outcomes. But the survival difference was not statistically significant. Disclosure: All authors have declared no conflicts of interest.

Efficacy and tolerability of adjuvant modified FOLFOX-4 following chemoradioterapy for stage III rectum adenocarcinoma.

e14586 Background: The aim of this study is to investigate efficacy and toxicity of adjuvant chemoradiotherapy with a modified 5-fluorouracil (5-FU), folinic acid, oxaliplatin (mFOLFOX-4) regimen f...